Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
The new program includes upstream and downstream process development and large-scale GMP production.
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Subscribe To Our Newsletter & Stay Updated
